Press Releases

Verastem Oncology Announces FDA Acceptance and Priority Review of New Drug Application for Avutometinib in Combination with Defactinib for the Treatment of Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer
December 30, 2024
Verastem Oncology Provides a Clinical Update for RAMP 203 Trial in Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer
December 18, 2024
Verastem Oncology to Present at the 7th Annual Evercore ISI HealthCONx Conference
November 26, 2024
Verastem Oncology Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates
November 6, 2024
Verastem Oncology Completes Rolling NDA Submission to the FDA for Avutometinib Plus Defactinib as a Treatment for Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer
October 31, 2024
Verastem Oncology to Participate in Upcoming Investor Conferences
October 31, 2024
Verastem Oncology Presents Positive Updated RAMP 201 Data for Avutometinib and Defactinib Combination in Recurrent Low-Grade Serous Ovarian Cancer at the International Gynecologic Cancer Society (IGCS) 2024 Annual Meeting
October 17, 2024
Verastem Oncology Announces Details for the Oral Presentation of the Mature RAMP 201 Data Evaluating Avutometinib Plus Defactinib in Recurrent Low-Grade Serous Ovarian Cancer at the IGCS 2024 Annual Meeting
October 9, 2024
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 7, 2024
Verastem Oncology to Present at the 2024 Cantor Global Healthcare Conference
September 10, 2024